Video Education With Result Dependent dIsclosure

Study acronym: VERDI
StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Final enrollment: 1334 participants (planned 1020)
    • Study completion date changed from estimate of Oct 1, 2026 to Sep 1, 2026
    • Eligibility criteria expanded, about 10 words
    • Site details revised
    • Study description expanded, about 5 words
  2. Primary completion pushed from Apr 30, 2026 to Aug 30, 2026
    • Study completion pushed from Sep 1, 2026 to Oct 1, 2026
    v10
  3. Primary completion date: Dec 31, 2025 to Apr 30, 2026v9
  4. Primary completion date: Sep 1, 2025 to Dec 31, 2025v8
  5. 2 versions Re-verified since Nov 15, 2023, no change to tracked fieldsv6-v7
Show 4 earlier versionsHide 4 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2022 to Aug 4, 2022
    • Site details revised
    v5
  2. Enrollment target: 660 to 1020v4
  3. Start date: Jun 2022 to Aug 2022v3
  4. Start date: Apr 2022 to Jun 2022v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Dana-Farber Cancer Institute
288 trials monitored
See 33 trials at risk
Breast Cancer
5,455 trials monitored
See 306 trials at risk
Colorectal Cancer
3,405 trials monitored
See 162 trials at risk
Prostate Cancer
2,550 trials monitored
See 165 trials at risk
and 5 more diseases
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Trial Details
NCT Number NCT05225428
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI)
Conditions
(from sponsor)		 Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma +1 more
Related terms Breast Neoplasms, Colorectal Neoplasms, Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma
Enrollment 1,334 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov